B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma

Hepatology

Volumn 30, Issue 2, 1999, Pages 422-429

  Tatsumi, Tomohide ^a   Takehara, Tetsuo ^a   Kanto, Tatsuya ^a   Kuzushita, Noriyoshi ^a   Ito, Akihiko ^a   Kasahara, Akinori ^a   Sasaki, Yutaka ^a   Hori, Masatsugu ^a   Hayashi, Norio ^a,b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 12; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TRANSFER; HELPER CELL; IMMUNIZATION; IMMUNOGENICITY; LIVER CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE TRANSFER TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION; INTERLEUKIN-12; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 0032765660     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300219     Document Type: Article

References (7)

1. Shirabe K, Takenaka K, Taketomi A, Kawahara N, Yamamoto K, Shimada M, Sugimachi K. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996;77:1050-1055.
2. Takayasu K, Wakao F, Moriyama N, Muramatsu Y, Yamazaki S, Kosuge T, Takayama T, et al. Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. HEPATOLOGY 1992;16:906-911.
3. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, Hamada E, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993;160:1023-1028.
4. Ichida T, Higuchi K, Arakawa K, Ohta H, Sugiyama K, Miyagiwa M, Nohzawa A, et al. Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2. Cancer Chemother Pharmacol 1990;2:45-48.
5. Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M. Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol 1993;9:332-336.
6. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, Sakata Y. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33: S145-S148.
7. Himoto T, Watanabe S, Nishioka M, Tanaka S, Saito M. Combination immunotherapy with OK432, recombinant granulocyte-colony stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma. Cancer Immunol Immunother 1996;42:127-131.